Get started
AMGEN INCAMGEN INCAMGEN INC

AMGEN INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

AMG trade ideas

Amgen (AMGN) Swing- Solid company - Has had downward trend for weeks but is now at support - For the six months ended 30 June 2021, Amgen, Inc. revenues increased less than 1% to $12.43B. - Net income decreased 42% to $2.11B. Revenues reflect Prolia segment increase of 20% to $1.57B - Other revenues segment increase of 28% to $721M, also reflect Enbrel segment decrease of14% to $2.07B, Neulasta segment decrease of 19% to $968M. - Net income was partially offset by Research and development increase of 7% to $2.05B (expense), Selling.
NASDAQ:AMGNLong
by DocKaz
another rejectionwhy would Amgen breakout here? Well, maybe it won't, and the goons pumping it on national television are taking the other side as it approaches a perennial resistance ceiling...or maybe the assumption of it's inclusion in the XLV weighted at 3.4% is enough for fund flows to push it over $260. With COVID raging in the prior December quarter, they could miss on earnings, and give strong guidance going forward, but at 21x, looks baked in. And this thing could get swept up in a market decline.
NASDAQ:AMGNShort
by QUANDRANTS
Buy $AMGN - NRPicks Feb 14Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in supportive care products for kidney disease and cancer. Flagship drugs include the red blood cell stimulators Epogen and Aranesp, the immune system stimulants Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen is one of the best positioned in the pharmaceutical industry. In 2020, the company generated higher earnings than in 2019, due to its strong product pipeline. Financially speaking, the company maintains controlled debt levels that it will be able to meet without any problems. Fundamentals: - Value - 8.8% estimated net earnings growth over the next 3 years. - P/E 19x vs. 29.6x industry P/E Technicals: - Price level cross MA 200 - 50 - Williams R% at -91% levels - RSI (41) Neutral - -2.8% average upside during the month On January 28th there was a market correction, which also affected Amgen. Although the correction lasted a couple of days, the share price continued to fall until $232.10. From this point, the stock recovered 2.5% and remains at these levels; however, the recovery channel should continue as there are no clear retracement fundamentals. In terms of technical factors, we can see that the SMA and Williams R% favor a buy decision.
NASDAQ:AMGNLong
by NewroadTrader
Amgen might move down soon according to the RSI....I have changed up how to best display projected movement. In the case of AMGN triggered a SELL on my RSI algorithm on March 19, 2021. Equities nearly always obey the signal and move down, but sometimes it may continue to move up first. I have placed two red boxes and two green boxes on the chart. The larger red box depicts all of the historical movement, from a percentage standpoint, that this stock has moved on the Daily chart after a SELL signal occurred. Therefore, this box represents 100% of previous movement upward before the stock finally moved downward. The smaller red box represents 50% of all historical movement upward, before the stock moved downward. The smaller box is more of a precise target for the potential top in this instance. The green boxes represent the same thing. In this instance, the smaller green box would be my projected target for the final bottom. The black dotted arrow represents median historical movement. Medians are a good metric, but they are just one of many I use when forecasting future movement. As always, the stock could decline the very next bar after the signal without looking back (therefore the red boxes would not come into play) or the stock may never decline (and the green boxes may never come into play). All statistics and the full analysis are available for free as always at the site below.
NASDAQ:AMGNShort
by StockSignaler